04-25-02

901611

AMSTER, ROTHSTEIN & EBENSTEIN

ATTORNEYS AT LAW

PATENTS . TRADEMARKS . COPYRIGHTS

90 PARK AVENUE NEW YORK, NEW YORK 10016

TELEPHONE: (212) 697-5995 FACSIMILE: (212) 286-0854 PATRICK BOLAND HOLLY PEKOWSKY

JOSEPH M. CASINO MICHAEL V. SOLOMITA MICHAEL P. KENNEY MARION P. METELSKI* MONIQUE L. RIBANDO

NEAL L. ROSENBERG DENISE A. LINDENAUER NANCY M. DODDERIDGE

April 24, 2002

via Express Mail

Assistant Commissioner for Patents Washington, DC 20231

"Express Mail" mailing label No. EV 034639866 US.

Date of Deposit: April 24, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Elie H. Gendloff

Signature:

Re: U.S. Patent Application Serial No. 10/038,760 - Small Entity Status

Title:

INHIBITORS OF ADP-RIBOSE TRANSFERASES, CYCLASES, AND

HYDROLASES, AND USES THEREOF

Inventor: Anthony A. Sauvé and Vern L. Schramm

Our File: 96700/725

Sir:

NIEL S. EBENSTEIN H. GOTTERIED

PHILIP H. GOTTFRIED
MICHAEL J. BERGER
NEIL M. ZIPKIN
ANTHONY F. LO CICERO
KENNETH P. GEORGE
ABRAHAM KASDAN, PH.D.
IRA E. SILFIN
CHESTER ROTHSTEIN

CHARLES R. MACEDO MARK J. ROSENBERG KENNETH M. BERNSTEIN

CRAIG J. ARNOLD SENIOR COUNSEL

OF COUNSEL JERRY DAINOW

> Enclosed please find the following documents for filing with the above-identified application in the names of Anthony A. Sauvé and Vern L. Schramm, entitled INHIBITORS OF ADP-RIBOSE TRANSFERASES, CYCLASES, AND HYDROLASES, AND USES THEREOF:

- an Information Disclosure Statement By Applicant Form PTO/SB/08A 1. with twenty-five (25) references attached; and
- a Return receipt postcard. 2.

Please acknowledge receipt of the enclosed documents by stamping the enclosed postcard and returning same.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN Attorneys for Applicants 90 Park Avenue New York, New York 10016 (212) 697-5995

Dated: New York, New York

April 24, 2002

Elie H. Gendloff

Registration No. 44,704

1	_ T	7
j	7	į
ſ	T) [
<	<	7
ר ו	_	

Please type a plus sign (+) inside this box

+ APR 2 4 2002

Under the Paperwork Reduction Act of 1995, no persons are required to respect to the Substitute for form 1449A/PTO

Apr 2 4 2002

Apr 2 4 2002

Apr 3 TRADENT

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

of

Sheet

PTO/SB/084 (08-00)

Approved for use through 10/31/2002, OMF 03-1-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of a collection of information unless it contains a valid OMB control number.

	THE STATE OF THE STATE OF THE OWNER	CONTROLLIGI	IIDEA
co	omplete if Known) DEN	PR
Application Number	10/038,760	77	ಲ
Filing Date	January 4, 2002	\Rightarrow	0
First Named Inventor	Anthony A. Sauvé	16)2
Group Art Unit	1614	-8	200
Examiner Name	to be assigned	2	
Attorney Docket Number	96700/725	8	

				U.S. PATENT DOCU	JMENTS	
Examiner Initials*	Cite No.1	U.S. Pater Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
						rigures Appeal
					- 	
		-	- 			·
					_	
ĺ						
						
					 	
						······································
					ļ	
						
	↓					
	ı					
				-	 	
					 	
			- 		 	
	-					
	- 					
						
	- 1					

				FORE	IGN PATENT DOCUMEN	TS		
Examiner	Cite	F	oreign Patent Do	cument	Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	
Initials*	No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T6
		<u> </u>					_	
					•			
								1
								\top
							·	1
					· · · · · · · · · · · · · · · · · · ·			1
						1	· · · · ·	\top

$\overline{}$		
Examiner	Date	
Cinnada.aa		1
Signature	Considered	
		L

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		us sign (+) inside this work Reduction Act o		→ + APR 2 4 2002	EVCE 49.2	Approv U. S. Patent and Tradem to a collection of informatic	ed for use through 10/31/2003	D/SB/08B 2. OMB 06: T OF COM	51-0031	+
		te for form 1449B/PT		St. is	2		mplete if Known	오	P	四
				A TRADEN	Α	pplication Number	10/038,760	$\overline{\Omega}$	P	Ш
ı	INF	JRMATIOI	N L	ISCLOSURE	щ	iling Date	January 4, 2002	Ż	- 20 -	
	STA	TEMENT	BY	APPLICANT		irst Named Inventor	Anthony A. Sauvé	Ħ	- -	$ \Pi $
ı					G	roup Art Unit	1614	æ	9	
L		(use as many s	sheet	's as necessary)	E	xaminer Name	to be assigned	5	20	
(s	Sheet	2	of	4	At	torney Docket Number	96700/725	8	22	/

96700/725

		OTHER PRIOR AND	
		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
B	-1	MEHTA, et al., The FASEB Journal, 10:1408-17, October 1996, "Human CD38, a cell-surface protein with multiple functions"	
	2	LEE, et al., J. Biol. Chem., 264:1608-15, January 1989, "Structural Determination of a Cyclic Metabolite of NAD+ with Intracellular Ca2+-mobilizing Activity"	
	3	PRASAD, et al., Nat. Struct. Biol., 3:957-64, November 1996, "Crystal structure of Aplysia ADP ribosyl cyclase, a homologue of the bifunctional ectozyme CD38"	
	4	LEE, et al., Nature Struct. Biol., 1:143-44, March 1994, "The crystal structure of cyclic ADP-ribose"	
	5	REYES-HARDE, et al., Proc. Natl. Acad. Sci. USA, 96:4061-66, March 1999, "Evidence of a role for cyclic ADP-ribose in long-term synaptic depression in hippocampus"	
	6	GALIONE, et al., Science, 253:1143-46, September 1991,"Ca2+-Induced Ca2+ Release in Sea Urchin Egg Homogenates: Modulation by Cyclic ADP-Ribose"	
	7	OKAMOTO H., Mol. Cell. Biochem., 193:115-18, March 1999, "The CD38-cyclic ADP-ribose signaling system in insulin secretion"	
	8	COCKAYNE, et al., Blood, 92:1324-33, August 1998, "Mice Deficient for the Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase CD38 Exhibit Altered Humoral Immune Responses"	
	۵	SAUVÉ, et al., Biochemistry, 37:13239-49, September 1998, "The Reaction Mechanism for CD38. A Single Intermediate Is Responsible for Cyclization, Hydrolysis, and Base-Exchange Chemistries"	
	10	SAUVÉ, et al., J. Am. Chem Soc., 122:7855-59, August 2000, "A Covalent intermediate in CD38 Is Responsible for ADP-Ribosylation and Cyclization Reactions"	
S	11	MULLER-STEFFNER, et al., J. Biol. Chem., 271:23967-72, September 1996, "Mechanism of Cyclization of Pyridine Nucleotides by Bovine Spleen NAD+ Glycohydrolase"	
		7/31/03	+
Examiner		Date 17 Amil 03	
Signature		Considered The Report OS	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

							•		
ase	type	а	plus	sign	(+)	inside	this	box	_

Sheet

Under the Paperwork Reduction Act of 1995,

PTO/SB/08B
Approved for use through 10/31/2002. ON PORTION OF CONTROL OF CONT

(08-00) 651-0031

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) of

Complete if Known Application Number 10/038,760 Filing Date January 4, 2002 First Named Inventor Anthony A. Sauvé Group Art Unit 1614 Examiner Name to be assigned Attorney Docket Number 96700/725

<u> </u>			OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Exa Initi	miner als	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
de		12	BERTHELIER, et al., Biochem. J., 330:1383-90, March 1998, "Human CD38 is an authentic NAD(P)+ glycohydrolase"	
		13	KIM, et al., Science, 261:1330-33, September 1993, "Synthesis and Degradation of Cyclic ADP-Ribose by NAD Gyclohydrolases"	
		14	NIEDBALLA and VORBRÜGGEN, J. Org. Chem., 39:3654-60, December 1974, "A General Synthesis of N-Glycosides. I.1 Synthesis of Pyrimidine Nucleosides"	
		15	MORRISON and WALSH, Adv. Enzymol. Relat. Areas Mol. Biol., 61:201-301, 1988, "The Behavior and Significance of Slow-Binding Enzyme Inhibitors"	
		16	PORTER, et al., J. Biol. Chem., 270:15551-56, June 1995, "Identification of the Active Site Nucleophile in Nucleoside 2-Deoxyribosyltransferase as Glutamic Acid 98"	
		17	ZECHEL and WITHERS, Acc. Chem Res., 33:11-18, 2000, "Glycosidase Mechanisms: Anatomy of a Finely Tuned Catalyst"	
		18	WONG, et al., J. Biol. Chem., 273:34057-62, December 1998, "Identification of Glu-540 as the Catalytic Nucleophile of Human beta-Glucuronidase Using Electrospray Mass Spectrometry"	
		19	WITHERS and STREET, J. Am. Chem. Soc., 110:8551-53, December 1988, "Identification of a Covalent alpha-D-Glucopyranosyl Enzyme Intermediate Formed on a beta-Glucosidase"	
		20	MULLER-STEFFNER, et al., J. Biol. Chem., 267:9606-11, May 1992, "Slow-binding Inhibition of NAD+ Glycohydrolase by Arabino Analogues of beta-NAD+"	
1		21	BERTHELIER, et al., Eur. J. Biochem., 267(10):3056-64, May 2000, "Probing ligand-induced conformational changes of human CD38"	
	2	7 2	MERKLER, et al., Biochemistry, 29:8358-64, September 1990, "The Rate Constant Describing Slow-Onset Inhibition of Yeast AMP Deaminase by Coformycin Analogues Is Independent of inhibitor Structure"	

Examiner Date Signature 17 April 03 Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box 🛶 🗍	+	
---	---	--

PTO/SB/082 (08-00)

Approved for use through 10/31/2002. OM T 151-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB contact Dumber.

					AT UNICOS IL CONTAINS & VAIIG ONE	CONTRACT DUMB	е
Substitu	ite for form 1449E	3/РТО		Co	emplete if Known	R	
INIE		ON DIG	CLOSURE	Application Number	10/038,760		
				Filing Date	January 4, 2002	Щ	_
STA	TEMEN.	T BY A	PPLICANT	First Named Inventor	Anthony A. Sauvé		_
				Group Art Unit	1614	8	_
	(use as ma	ny sheets a:	s necessary)	Examiner Name	to be assigned	-	
heet	4	of	4	Attorney Docket Number	96700/725	- 290	_

OTHER PRIOR ART

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
de	28	LUND, et al., Immunol. Rev., 161:79-93, February 1998, "CD38: a new paradigm in lymphocyte activation and signal transduction"
A.	24	LEE, et al., Mol. Cell. Biochem., 193:89-98, March 1999, "Structures and activities of cyclic ADP-ribose, NAADP and their metabolic enzymes"
0	ن 25	LEE, H.C., Recent Prog. Horm. Res., 51:355-88, 1996, "Modulator and Messenger Functions of Cyclic ADP-Ribose in Calcium Signaling"
xaminer		73103 Date Considered 11 April 03

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.